Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Crinetics Pharmaceuticals excels in 2023 with promising pipeline advancements

Crinetics Pharmaceuticals had a successful year in 2023, with promising results from their lead candidate, paltusotine, in acromegaly and carcinoid syndrome, supported by a strong financial position and progress in key clinical trials.
While facing challenges in response rates and drug positioning, Crinetics remains focused on advancing their pipeline, exploring new treatment pathways, and optimizing drug characteristics for efficacy and safety.
Opportunities lie in expanding the therapeutic portfolio, upcoming data releases, and engagement at industry events to drive awareness, investor confidence, and potential market growth for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals reports positive Q1 results and pipeline advancements

Crinetics Pharmaceuticals showcased positive clinical results and a strong financial position in Q1 2024, with plans for Phase III studies and NDA filings.
The company's focus on injectable depot therapies addresses treatment burden challenges, while questions raised during the call highlight areas for further development.
Anticipation for future updates from the pipeline and opportunities for market expansion through strategic relationships position Crinetics for potential growth.
Despite facing a high cash burn rate, Crinetics Pharmaceuticals' progress in key therapeutic areas and financial strengthening provide a foundation for future success.

Crinetics Pharmaceuticals excels in Q3, poised for growth and innovation

Crinetics Pharmaceuticals is on track for significant growth with advancements in their pipeline and a strong financial position. While facing challenges in upcoming trials and product launches, the company has ample opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Commenced dosing in Phase 3 PATHFNDR-1 study –

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts

Crinetics Pharmaceuticals' Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 851,306 shares at $17.62 per share. The private placement will yield gross proceeds of $15.0 million and is expected to close on August 2, 2021, subject to the satisfaction of customary closing conditions.

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option -

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Garlan Adams to the newly created role of general counsel. Ms. Adams brings to Crinetics more than two decades of experience managing legal and compliance matters associated with the development and commercialization of innovative pharmaceutical and biotechnology products.

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021

Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $75.0 million. Investors in the offering included Deep Track Capital, Bain Capital Life Sciences, and Driehaus Capital Management, with participation from other new and existing stockholders.

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

Crinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call Transcript

Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

Oral and Late-breaker Presentations Selected on the Company's ACTH Antagonist and Congenital HI Programs Oral and Late-breaker Presentations Selected on the Company's ACTH Antagonist and Congenital HI Programs

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

- Details of New Paltusotine Tablet Formulation to be Unveiled -

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that CRN04894, the company's lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as Cushing's disease and congenital adrenal hyperplasia (CAH), has advanced into the clinic. Based on encouraging preclinical results, Crinetics has initiated a double-blind, randomized, placebo-controlled Phase 1 study of this orally administered, nonpeptide small molecule drug candidate in healthy volunteers. This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation.

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease (CRN04894) Advances into Phase 1 Study

Phase 1 study is designed to provide clinical proof-of-concept by taking advantage of established methods in endocrinology Phase 1 study is designed to provide clinical proof-of-concept by taking advantage of established methods in endocrinology

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below:  

Crinetics Pharmaceuticals to Participate in December Investor Conferences

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Peter Trainer, MD, FRCPE to the position of Vice President of Clinical Endocrinology.

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals (CRNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings?

Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trial s of oral paltusotine for the treatment of acromegaly

Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy  

Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint

SAN DIEGO, Sept.  21, 2020  (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted rare pediatric disease designation (“RPD”) for CRN04777, an investigational, orally available, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). Congenital HI is a devastating rare disease in which infants are born with life threatening hypoglycemia (low blood glucose) due to excess insulin secretion.

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

SAN DIEGO, Sept.  04, 2020  (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that a presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE) on September 8, 2020. In addition, a poster summarizing results from Phase 1 bioavailability studies of paltusotine (formerly CRN00808), the company’s lead candidate for the treatment of acromegaly, will be available to congress attendees from September 5-9, 2020.

Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology

SAN DIEGO, Sept.  03, 2020  (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Camille L. Bedrosian, M.D. as an independent member of its board of directors. Dr. Bedrosian brings over 25 years of experience leading drug development efforts for rare disease products and building successful medical affairs and clinical development teams.

Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D.

Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.

News for Crinetics Pharmaceuticals Inc Stock (CRNX)